

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the subject application.

Listing of Claims:

Claims 1-23 (cancelled).

¹
Claim ~~24~~ (previously presented): An immunogenic composition formulated for local administration directly to a mucous membrane comprising a recombinant HIV-1 envelope protein comprising a mutated V3 loop, wherein the mutated V3 loop comprises the GPGRAPH (SEQ ID NO: 1) hexamer sequence flanked by the two basal cysteines but lacks all or a portion of the rest of the V3 loop, said recombinant HIV-1 envelope protein being anchored onto preformed liposomes.

²
Claim ~~25~~ (previously presented): The immunogenic composition of claim ~~24~~ further comprising adjuvants.

³
Claim ~~26~~ (previously presented): The immunogenic composition of claim ~~25~~, wherein the adjuvants are derivatives comprising divalent or trivalent ions or muramylpeptide derivatives.

⁴
Claim ~~27~~ (previously presented): The immunogenic composition of claim ~~26~~, wherein the derivatives comprising divalent or trivalent ions are aluminum hydroxide or calcium phosphate.

⁵
Claim ~~28~~ (previously presented): The immunogenic composition of claim ~~27~~, wherein the envelope protein is anchored onto unilamellar synthetic lipid vesicles.

⁶
Claim ~~29~~ (previously presented): The immunogenic composition of claim ~~28~~ wherein the vesicles comprise a molar ratio of phosphatidylcholine to cholesterol of about 8:1, and which have a size of between 70 and 150 nm.

⁷
Claim ~~30~~ (previously presented): The immunogenic composition of claim ~~29~~, wherein the size of the vesicles is about 90 nm.

⁸
Claim ~~31~~ (previously presented): The immunogenic composition of claim ~~24~~, wherein the envelope protein is selected from the group consisting of gp160 and gp120 Env proteins.

Claims 32-33 (cancelled).

⁹
Claim ~~34~~ (previously presented): The immunogenic composition of claim ~~24~~, wherein the immunogenic composition is formulated for administering rectally or vaginally.

¹⁰
Claim ~~35~~ (previously presented): The immunogenic composition of claim ~~24~~, wherein the immunogenic composition comprises at least glycerol or a glycerol/glycerine-based mixture.

¹¹
Claim ~~36~~ (previously presented): The immunogenic composition of claim ~~24~~ further comprising trehalose.